Garry Nolan

Garry Nolan, PhD, Rachford and Carlota A. Harris Professor, Department of Pathology, Stanford University School of Medicine. 

Research Description: Dr. Nolan’s areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. His group at Stanford pioneered development and utilization of machine learning algorithms to interpret the large high-dimensional datasets being produced by CyTOF, MIBI, and CODEX. Use of CyTOF mass cytometry for high-dimensional single- cell proteomics has been widely adopted worldwide. Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, infection, and other inflammatory events—including detailed substructures of the immune system as they relate to varied tissue contexts—to enable wholly new understandings for better management of disease and clinical outcomes. One area of current investigation is the human pancreas, enabled by reliable procurement of primary tissue samples through SDRC Core. Based on Dr. Nolan’s pioneering work, CyTOF and CODEX are poised to be the next revolution in single cell pancreas analysis, and is currently being applied by groups at Stanford and elsewhere (including the NIH Human Islet Resource Network) to delineate islet development and biology in health and diabetes or pre-diabetes. Dr. Nolan serves on the Advisory Committee to the Diabetes Immune Monitoring Center (DIMC) with Davis, Fathman, Maecker and others.

Selected relevant publications (Stanford DRC members in BOLD):

  1. Lee IT, Nakayama T, Wu CT, Goltsev Y, Jiang S, Gall PA, Liao CK, Shih LC, Schürch CM, McIlwain DR, Chu P, Borchard NA, Zarabanda D, Dholakia SS, Yang A, Kim D, Chen H, Kanie T, Lin CD, Tsai MH, Phillips KM, Kim R, Overdevest JB, Tyler MA, Yan CH, Lin CF, Lin YT, Bau DT, Tsay GJ, Patel ZM, Tsou YA, Tzankov A, Matter MS, Tai CJ, Yeh TH, Hwang PH, Nolan GP, Nayak JV, Jackson PK. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat Commun. 2020 Oct 28;11(1):5453. doi: 10.1038/s41467-020-19145-6. PMID: 33116139; PMCID: PMC7595232. 

  2. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, Bodenmiller B, Campbell P, Carninci P, Clatworthy M, Clevers H, Deplancke B, Dunham I, Eberwine J, Eils R, Enard W, Farmer A, Fugger L, Göttgens B, Hacohen N, Haniffa M, Hemberg M, Kim S, Klenerman P, Kriegstein A, Lein E, Linnarsson S, Lundberg E, Lundeberg J, Majumder P, Marioni JC, Merad M, Mhlanga M, Nawijn M, Netea M, Nolan G, Pe'er D, Phillipakis A, Ponting CP, Quake S, Reik W, Rozenblatt-Rosen O, Sanes J, Satija R, Schumacher TN, Shalek A, Shapiro E, Sharma P, Shin JW, Stegle O, Stratton M, Stubbington MJT, Theis FJ, Uhlen M, van Oudenaarden A, Wagner A, Watt F, Weissman J, Wold B, Xavier R, Yosef N; Human Cell Atlas Meeting Participants. The Human Cell Atlas. Elife. 2017 Dec 5;6:e27041. doi: 10.7554/eLife.27041. PMID: 29206104; PMCID: PMC5762154. 

  3. Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC, Nolan GP, Rosen ST, Tan P, Yen Y, Zarrinpar A. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol. 2020 May;38(5):497-518. doi: 10.1016/j.tibtech.2019.12.021. PMID: 31980301.